New research reveals that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who stop conventional diet and exercise programs.
Research printed in a major medical journal shows that while obese individuals can lose about a fifth of their total mass while using the jabs, the weight returns at an average rate of nearly a kilo each month once they quit.
"Individuals buying such medications must be cognizant of the risk of rapid rebound weight gain when the treatment concludes," warns researcher Dr. Susan Jebb.
That rate of regain means a reversion to original mass in about 18 months.
Weighing Treatments
The analysis, which examined 37 of trials involving over 9,000 of participants, contrasted the results of the injectable medications with conventional dieting.
The team emphasize that people who shed pounds through diet and exercise generally have a slower creep back—around 100 grams monthly—once they finish.
The Reason for the Rapid Regain
Experts suggest the mode of action of the drugs is key to understanding the amplified rebound.
The injections copy a body's own chemical called GLP-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations far above than normal may cause the system to produce less of its endogenous GLP-1, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement means appetite is unsuppressed, making overeating a significant risk."
An Ongoing Condition?
The NHS advise the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians argue that, given the high risk of weight regain, the treatment might need to be life-long.
This view is echoed by pharmaceutical companies, who state that the findings "emphasize the persistent character of excess weight," similar to managing conditions like hypertension.
Patient Accounts
People who have stopped the jabs describe a powerful return of appetite.
"It felt as if something that goes on and you become extremely hungry," described one woman.
This challenge is compounded if patients have not adopted lasting lifestyle or habit changes during treatment.
Widespread Use
Figures suggest that millions of people in the UK have used these injections in the past year, with demand remaining high.
- Adoption is higher among females compared to males.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Ultimately, experts caution that while these medications are effective tools for weight loss, they are not a magic solution and maintained weight loss relies on integrated behavioural management.
